Enovis (NYSE:ENOV) Updates FY 2026 Earnings Guidance

Enovis (NYSE:ENOV) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 3.520-3.730 for the period, compared to the consensus earnings per share estimate of 3.630. The company issued revenue guidance of $2.3 billion-$2.4 billion, compared to the consensus revenue estimate of $2.3 billion.

Enovis Trading Down 2.7%

Enovis stock traded down $0.73 during trading on Friday, reaching $26.52. 1,537,846 shares of the company were exchanged, compared to its average volume of 944,320. Enovis has a 52-week low of $21.00 and a 52-week high of $37.85. The company has a market capitalization of $1.53 billion, a P/E ratio of -1.33 and a beta of 1.41. The company has a debt-to-equity ratio of 0.87, a current ratio of 2.04 and a quick ratio of 1.04. The stock’s 50 day simple moving average is $23.86 and its two-hundred day simple moving average is $25.80.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping analysts’ consensus estimates of $0.82 by $0.07. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.The firm had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. During the same quarter last year, the business posted $0.81 earnings per share. The firm’s revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts expect that Enovis will post 3.62 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on ENOV shares. Weiss Ratings reiterated a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. BTIG Research upped their price objective on Enovis from $41.00 to $43.00 and gave the company a “buy” rating in a report on Thursday, February 26th. Evercore reiterated an “outperform” rating and issued a $36.00 price objective on shares of Enovis in a report on Friday. Wells Fargo & Company reduced their target price on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday. Finally, Needham & Company LLC lifted their target price on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.17.

Insider Buying and Selling

In other Enovis news, insider Oliver Engert bought 1,000 shares of Enovis stock in a transaction on Friday, February 27th. The shares were bought at an average price of $25.50 per share, for a total transaction of $25,500.00. Following the completion of the transaction, the insider directly owned 43,640 shares of the company’s stock, valued at $1,112,820. This trade represents a 2.35% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Insiders acquired a total of 5,000 shares of company stock valued at $121,983 in the last quarter. 2.90% of the stock is owned by insiders.

Trending Headlines about Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported first-quarter EPS of $0.89, topping estimates of $0.82, while revenue of $589.15 million also beat expectations. Revenue rose 5.4% year over year, signaling solid demand and execution. Article Title
• Positive Sentiment: The company reaffirmed 2026 free cash flow conversion of greater than 25%, suggesting management still sees healthy cash generation despite Middle East and tariff headwinds. Article Title
• Neutral Sentiment: Enovis also reiterated full-year 2026 guidance, with EPS of $3.52 to $3.73 and revenue of $2.3 billion to $2.4 billion, which was roughly in line with analyst expectations and may reassure investors about the company’s near-term outlook. Article Title
• Neutral Sentiment: Wells Fargo lowered its price target on Enovis to $40 from $42, but kept an overweight rating, indicating continued upside potential despite a slightly more cautious valuation view. Article Title

Hedge Funds Weigh In On Enovis

Hedge funds have recently bought and sold shares of the company. Creative Planning acquired a new position in Enovis during the 3rd quarter worth about $274,000. Mackenzie Financial Corp lifted its stake in Enovis by 31.3% during the 3rd quarter. Mackenzie Financial Corp now owns 9,555 shares of the company’s stock worth $290,000 after acquiring an additional 2,275 shares in the last quarter. State of Wyoming lifted its stake in Enovis by 555,600.0% during the 2nd quarter. State of Wyoming now owns 5,557 shares of the company’s stock worth $174,000 after acquiring an additional 5,556 shares in the last quarter. FORA Capital LLC acquired a new position in Enovis during the 2nd quarter worth about $304,000. Finally, Corient Private Wealth LLC lifted its stake in Enovis by 37.3% during the 2nd quarter. Corient Private Wealth LLC now owns 10,474 shares of the company’s stock worth $328,000 after acquiring an additional 2,847 shares in the last quarter. Institutional investors and hedge funds own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.